药学研究2024，Vol.43Issue(5)：487-494,8.DOI:10.13506/j.cnki.jpr.2024.05.013
新型降脂药物PCSK9抑制剂在动脉粥样硬化心血管疾病的研究现状
Research status of new lipid-lowering drugs PCSK9 inhibitors in arteriosclerosis cardiovascular disease
摘要
Abstract
Atherosclerosis is an early pathological change of many cardiovascular diseases.Lipid metabolism disorder is one of the most important risk factors of atherosclerotic cardiovascular disease(ASCVD).Proprotein convertase subtilisin/kexin type 9(PCSK9)is a key protein in lipid metabolism.It can bind to low-density lipoprotein receptor(LDLR)and degrade LDLR to prevent the clearance of low-density lipoprotein,resulting in increased low-density lipoprotein cholesterol(LDL-C)levels,and increasing risk of cardiovascular disease.PCSK9 is also involved in the production of inflammatory cytokines,endothelial dysfunction and the formation of atherosclerotic plaques.A number of studies have shown that PCSK9 is a promising new target for the treatment of ASCVD.PCSK9 inhibitors are currently a new type of drug for the treatment of hypercholesterolemia.This article reviewed the role of PCSK9 inhibitors in atherosclerosis and the research progress of drugs,so as to provide reference for clinical medication.关键词
前蛋白转化酶枯草杆菌蛋白酶/kexin9型抑制剂/动脉粥样硬化/人前蛋白转化酶枯草溶菌素9/动脉粥样硬化性心血管疾病/胆固醇/低密度脂蛋白胆固醇Key words
Proprotein convertase subtilisin/kexin type 9 inhibitors/Atherosclerosis/Human proprotein convertase subtilisin/kexin type 9 inhibitor/ASCVD/Cholesterol/Low-density lipoprotein cholesterol分类
医药卫生引用本文复制引用
马国文,刘世昌,王海亮,姜文妍,王学健..新型降脂药物PCSK9抑制剂在动脉粥样硬化心血管疾病的研究现状[J].药学研究,2024,43(5):487-494,8.基金项目
山东省高等学校科技计划项目(No.J15LM58) （No.J15LM58）
